Wolfe Research Assumes Repligen at Outperform, Announces Price Target of $145

Benzinga Newsdesk www.benzinga.com Neutral 53.4%

Neg 0% Neu 53.4% Pos 0%

Wolfe Research analyst Mike Polark assumes Repligen (NASDAQ:RGEN) with a Outperform rating and announces Price Target of $145.